About us
Pioneering dry powder inhalation products
Pharmaceutical companies worldwide are continuously developing more effective products for preventing and treating various medical conditions. Iconovo stands alongside these companies to push the boundaries of what is achievable with inhaled therapies.
Our comprehensive solutions, where inhalers and dry powder formulations are optimized for desired functionality, provide an attractive way to shorten time-to-market. Iconovo enables challengers in the pharmaceutical industry to quickly and cost-effectively develop generic inhalation products, where the lower cost can be directly passed on to the patients. We also assist innovative companies in developing new, inhaled original medicines – all at a low risk.
Iconovo is a leading Swedish CDMO company, offering innovative and effective inhalation platforms to the international pharmaceutical industry. We have several types of patented inhalers that can create significant commercial opportunities for the development of both new pharmaceuticals and generic medicine.
We are a well-established company with patent families and an extensive product pipeline. Our strategy is focused on three core areas: CDMO business, License agreements, and Nordic Drug Sales.
Iconovo is listed on Nasdaq First North Growth Market: ICO.
